Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,124 matching trials from the live ClinicalTrials.gov search.
Conditions
Influenza, Human
Interventions
mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
54,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
161
States / cities
Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement

NCT06571747
Conditions
Cardiovascular Diseases, Influenza, Behavior, Social
Interventions
Cardiovascular-Focused Nudge Communication
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
3,668,428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Pleasanton, California • Bethesda, Maryland
Conditions
Diabetes, Foot Ulcer
Interventions
Tailored Intervention (TI), Current Practice (CP)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Influenza
Interventions
VAX128, Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
65 Years and older
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Influenza, Human
Interventions
Elderberry Extract, Placebos
Drug
Lead sponsor
michael macknin
Other
Eligibility
5 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

NCT02290509
Conditions
Influenza
Interventions
Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Completed No phase listed Observational Accepts healthy volunteers

Avian Influenza Studies In Lebanon

NCT01107262
Conditions
Avian Influenza, Virus Diseases
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Completed No phase listed Observational Accepts healthy volunteers

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

NCT06130345
Conditions
SARS-CoV-2
Interventions
SPIKEVAX
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
15,196,685 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home

NCT00812110
Conditions
Influenza
Interventions
Influenzae vaccine
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Inactivated Influenza Vaccine
Interventions
2005-2006 trivalent inactivated influenza vaccine
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
42 Days to 84 Days
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

NCT01427309
Conditions
Influenza
Interventions
High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
31,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
105
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 88 more
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

NCT01623232
Conditions
Influenza Vaccines, Aged
Interventions
MAS-1 adjuvant and influenza HA antigen, standard dose, inactivated trivalent influenza vaccine (TIV)
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Conditions
Inflammatory Bowel Diseases
Interventions
Influenza vaccine, COVID-19 vaccine
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Interventions
Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
Radiation · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Months to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Rochester, New York
Conditions
Avian Influenza
Interventions
H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Durham, North Carolina • Nashville, Tennessee • Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

NCT02289820
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
MEDI7510, IIV
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Orlando, Florida • South Miami, Florida • Kansas City, Missouri + 2 more
Terminated No phase listed Observational Accepts healthy volunteers

Vaccination Response in Individual Monozygotic Twins

NCT02296359
Conditions
Individuality, Asthma, Immune System and Related Disorders
Interventions
Influenza Vaccination
Biological
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
East Lansing, Michigan
Completed Phase 2 Interventional Results available

Statin Therapy in Acute Influenza

NCT02056340
Conditions
Influenza
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Completed Not applicable Interventional Accepts healthy volunteers

Mail Outreach To Increase Vaccination Acceptance Through Engagement

NCT02243774
Conditions
Influenza, Human, Influenza, Human Flu
Interventions
Core letter signed by Surgeon General, Core letter signed by the Director of the National Vaccine Program, Core letter signed by Surgeon General + implementation prompt, Core letter signed by SG + enhanced implementation prompt
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
66 Years and older
Enrollment
228,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland